Delcath Systems reports Q1 2026 financial results
Revenue reaches $25M, up from $19.8M. Issues $100M 2026 guidance. Highlights HEPZATO growth and CHOPIN trial publication.
See the latest news and media coverage for Delcath Systems. We track all announcements, press releases, and industry mentions in real time, all in one place.
Interventional oncology company focused on liver cancer treatments
delcath.comLast updated
In short: Delcath Systems reported robust revenue growth, issued a $100M 2026 guidance, and expanded clinical evidence for its HEPZATO KIT and CHEMOSAT system.
Revenue reaches $25M, up from $19.8M. Issues $100M 2026 guidance. Highlights HEPZATO growth and CHOPIN trial publication.
CHEMOSAT Hepatic Delivery System for Melphalan is recommended as a liver-directed therapy for uveal melanoma with liver metastases. It supports improved survival from Phase 3 trials.
Results in The Lancet Oncology show PHP with immunotherapy improves PFS, OS, and response rates in metastatic uveal melanoma.
Revenue reaches $85.2 million with $2.7 million net income. HEPZATO KIT drives growth; 2026 guidance projects at least $100 million revenue. 28 active centers; 140% procedure volume increase.
Detailed price information for Delcath Systems Inc (DCTH-Q) from The Globe and Mail including charting and trades.
Site activation expectations shifted from Q4 2025's "targeting 40 active treatment centers by the end of 2026" (CEO Michel) to Q1 2026's "modifying our year-end...
Thank you, and welcome to Delcath Systems First Quarter 2026 Earnings Call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell...
Liver-dominant metastatic breast cancer remains a significant clinical challenge, as progression in the liver can be a major driver of morbidity and may limit the...
Track Delcath Systems and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.